BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25951319)

  • 1. Preoperative Assessment of TERT Promoter Mutation on Thyroid Core Needle Biopsies Supports Diagnosis of Malignancy and Addresses Surgical Strategy.
    Crescenzi A; Trimboli P; Modica DC; Taffon C; Guidobaldi L; Taccogna S; Rainer A; Trombetta M; Papini E; Zelano G
    Horm Metab Res; 2016 Mar; 48(3):157-62. PubMed ID: 25951319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital.
    Perdana AB; Putri RI; Rachmawati R; Andinata B; Brahma B
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3267-3277. PubMed ID: 33247684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
    Choi SH; Baek JH; Lee JH; Choi YJ; Ha EJ; Song DE; Kim JK; Chung KW; Kim TY; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):607-13. PubMed ID: 26215382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.
    Liu R; Xing M
    Endocr Relat Cancer; 2014 Oct; 21(5):825-30. PubMed ID: 25121551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.
    Cohen Y; Rosenbaum E; Clark DP; Zeiger MA; Umbricht CB; Tufano RP; Sidransky D; Westra WH
    Clin Cancer Res; 2004 Apr; 10(8):2761-5. PubMed ID: 15102681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative detection of TERT promoter and BRAFV600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules.
    Giorgenon TMV; Carrijo FT; Arruda MA; Cerqueira TLO; Barreto HR; Cabral JB; Silva TMD; Magalhães PKR; Maciel LMZ; Ramos HE
    Arch Endocrinol Metab; 2019; 63(2):107-112. PubMed ID: 30916166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
    Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
    Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
    Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
    JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas.
    Nakao T; Matsuse M; Saenko V; Rogounovitch T; Tanaka A; Suzuki K; Higuchi M; Sasai H; Sano T; Hirokawa M; Miyauchi A; Kawakami A; Mitsutake N
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):790-799. PubMed ID: 34322882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
    Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
    Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
    Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases.
    Hysek M; Hellgren LS; Stenman A; Darai-Ramqvist E; Ljung E; Schliemann I; Condello V; Larsson C; Zedenius J; Jatta K; Juhlin CC
    Diagn Cytopathol; 2023 Jun; 51(6):331-340. PubMed ID: 36870048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
    Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
    [No Abstract]   [Full Text] [Related]  

  • 20. TERT promoter mutations in thyroid cancer.
    Liu R; Xing M
    Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.